Insulin secreted from genetically engineered intestinal cells reduces blood glucose levels in diabetic mice

Current Gene Therapy

Volumn 13, Issue 4, 2013, Pages 229-239

  Rasouli, Mina ^a   Allaud, Zeenathul N ^a   Omar, Abdul R ^a   Ahmad, Zalina ^a  

^a UNIVERSITY PUTRA MALAYSIA   (Malaysia)

Author keywords

Chitosan nanoparticles; Diabetes gene therapy; In vivo; K cells and L cells

Indexed keywords

CHITOSAN; INSULIN; NANOPARTICLE; PLASMID DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD GLUCOSE MONITORING; BODY WEIGHT; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; GENE TARGETING; GENE THERAPY; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; INTESTINE CELL; KILLER CELL; L CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; TREATMENT RESPONSE;

ANIMALS; BLOOD GLUCOSE; CHITOSAN; DIABETES MELLITUS; ENTEROENDOCRINE CELLS; GENE TRANSFER TECHNIQUES; GENETIC ENGINEERING; HUMANS; INSULIN; INTESTINES; MICE; MICE, INBRED NOD; NANOPARTICLES;

EID: 84888082418     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/15665232113139990002     Document Type: Article

References (24)

1. Crofford OB. Diabetes control and complications. Ann Rev Med 1995; 46: 267-79.
2. Yoon JW, Jun HS. Recent advances in insulin gene therapy for type 1 diabetes. Trends Mol Med 2002; 8(2): 62-8.
3. Somia N, Verma IM. Gene therapy: trials and tribulations. Nat Rev Genet 2000; 1(2): 91-9.
4. Flotte TR. Gene therapy: the first two decades and the current state-of-the-art. J Cell Physiol 2007; 213(2): 301-5.
5. Yechoor V, Chan L. Gene therapy progress and prospects: gene therapy for diabetes mellitus. Gene Ther 2005; 12(2): 101-7.
6. Lynch DR, Strittmatter SM, Venable JC, Snyder SH. Enkephalin convertase in the gastrointestinal tract an associated organs characterized and localized with [3H]guanidinoethylmercaptosuccinic acid. Endocrinology 1987; 121(1): 116-26.
7. Vilsboll T, Krarup T, Madsbad S, Holst JJ. Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects. Regul Peptides 2003; 114(2-3): 115-21.
8. Efendic S, & Portwood N. Overview of incretin hormones. Horm Metab Res 2004; 36(11-12), 742-746.
9. Burcelin R. The incretins: a link between nutrients and well-being. Br J Nutr 2005; 93 Suppl 1, S147-156.
10. Cheung AT, Dayanandan B, Lewis JT, Korbutt GS, Rajotte RV, Bryer-Ash M, et al. Glucose-dependent insulin release from genetically engineered K cells. Science 2000; 290(5498): 1959-62.
11. Ramshur EB, Rull TR, Wice BM. Novel insulin/GIP co-producing cell lines provide unexpected insights into Gut K-cell function in vivo. J Cell Physiol 2002; 192(3): 339-50.
12. Tang SC, Sambanis A. Differential rAAV2 transduction efficiencies and insulin secretion profiles in pure and co-culture models of human enteroendocrine L-cells and enterocytes. J Gene Med 2004; 6(9): 1003-13.
13. Rasouli M, Ahmad Z, Omar AR, Allaudin ZN. Engineering an L-cell line that expresses insulin under the control of the glucagon-like peptide-1 promoter for diabetes treatment. BMC Biotechnol 2011; 11: 99.
14. Ahmad Z, Rasouli M, Azman AZ, Omar AR. Evaluation of insulin expression and secretion in genetically engineered gut K and L-cells. BMC Biotechnol 2012; 12: 64.
15. Cryan SA, O'Driscoll CM. Mechanistic studies on nonviral gene delivery to the intestine using in vitro differentiated cell culture models and an in vivo rat intestinal loop. Pharmaceut Res 2003; 20(4): 569-75.
16. Dhaliwal S, Jain S, Singh HP, Tiwary AK. Mucoadhesive micro-spheres for gastroretentive delivery of acyclovir: in vitro and in vivo evaluation. AAPS J. 2008; 10(2): 322-30.
17. Mao HQ, Roy K, Troung-Le VL, Janes KA, Lin KY, Wang Y, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 2001; 70(3): 399-421.
18. Tong H, Qin S, Fernandes JC, Li L, Dai K, Zhang X. Progress and prospects of chitosan and its derivatives as non-viral gene vectors in gene therapy. Curr Gene Ther 2009; 9(6): 495-502.
19. Chen J, Yang WL, Li G, Qian J, Xue JL, Fu SK, et al. Transfection of mEpo gene to intestinal epithelium in vivo mediated by oral delivery of chitosan-DNA nanoparticles. World J Gastroenterol 2004; 10(1): 112-6.
20. Bowman K, Leong KW. Chitosan nanoparticles for oral drug and gene delivery. Int J Nanomedicine 2006; 1(2): 117-28.
21. Han J, Lee HH, Kwon H, Shin S, Yoon JW, Jun HS. Engineered enteroendocrine cells secrete insulin in response to glucose and reverse hyperglycemia in diabetic mice. Mol Ther 2007; 15(6): 1195-202.
22. NCBI. National Center for Biotechnological Information. http://www.ncbi.nlm.nih.gov/BLAST/Blast.cgi
23. Nell LJ, Virta VJ, Thomas JW. Application of a rapid enzyme-linked immunosorbent microassay (ELISA) to study human anti-insulin antibody. Diabetes 1985; 34(1): 60-6.
24. Fineberg SE, Kawabata TT, Finco-Kent D, Fountaine RJ, Finch GL, Krasner AS. Immunological responses to exogenous insulin. Endocr Rev 2007; 28(6): 625-52.